Venture-backed medical device company EOS Imaging has raised €38m in its IPO on NYSE Euronext. Based on the opening trade price, the company is valued at approximately €120m.
Investors include medical device-focused venture capital firm NBGI Ventures and Edmond de Rothschild Investment Partners, which has been the lead investor and the company’s largest shareholder since 2005.
Aris Constantinides, investment director of NBGI Ventures, said, “At the time we first invested in the company, we recognised the potential to create a global business. Since then, we have made a significant contribution to the business operationally, including introducing its current chairman, Stephane Sallmard, and in working closely with management in developing its commercial model. The successful IPO now positions EOS Imagine for the next stage of its development.”
Recently, NBGI’s portfolio company Technolas Perfect Vision entered into a definitive agreement to be acquired by Bausch & Lomb for €450m.
With over €100m in total commitments under management, NBGI Ventures’ investments include Advanced Cardiac Therapeutics, BoneSupport, Cellnovo, EOS Imagine, Estech, Forth Photonics, Quanta Fluid Solutions, Reverse Medical, SuperSonic Imagine, Symetis, Technolas/2010 Perfect Vision and Upfront Chromatography.
This IPO is the second listing on a major public market for a company from the BioDiscovery 2 fund managed by Edmond de Rothschild Investment Partners., which to date have completed eight trade sales and nine IPOs.
Copyright © 2012 AltAssets